Critical

Anticoagulant reversal (warfarin/vitamin K antagonist and DOAC reversal; vitamin K deficiency bleeding; incl. andexanet alfa, idarucizumab, PCC)

Coagulation / bleeding emergency · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Structured reversal of anticoagulant-associated major bleeding or need for emergency surgery. Warfarin: 4-factor PCC + IV vitamin K. Dabigatran: idarucizumab. Factor Xa inhibitors (apixaban/rivaroxaban/edoxaban): andexanet alfa or PCC. Also covers vitamin K deficiency coagulopathy. Complements the broader 'Major haemorrhage on anticoagulant' protocol with agent-specific detail.

Red flags

  • Intracranial haemorrhage on anticoagulant (reverse immediately, do not wait for levels)
  • Haemodynamic instability / massive GI or retroperitoneal bleed
  • Spinal/epidural haematoma (back pain + neuro signs)
  • Mechanical heart valve (reversal increases valve thrombosis risk - urgent cardiology/haematology)
  • Thrombotic event after reversal (andexanet/PCC prothrombotic)

Assessment

Differential diagnosis

  • Over-anticoagulation without bleeding (high INR alone)
  • DIC / liver failure coagulopathy (give vitamin K/factors but treat cause)
  • Dilutional/trauma coagulopathy (massive transfusion pathway)
  • Acquired/inherited bleeding disorder unmasked
  • Platelet dysfunction (antiplatelet agents, uraemia)

Investigations

  • Identify exact agent, dose, timing of LAST dose, and indication for anticoagulation
  • INR/PT/APTT, fibrinogen, FBC, U&E (renal clearance affects DOAC levels), LFTs, group & save/crossmatch
  • Anti-Xa level (apixaban/rivaroxaban-calibrated) and dilute thrombin time/ecarin for dabigatran where available
  • A normal thrombin time effectively excludes clinically relevant dabigatran; normal anti-Xa excludes relevant Xa-inhibitor level
  • Imaging to localise/quantify bleed (CT head for intracranial haemorrhage etc.)

Management

  • Stop anticoagulant; resuscitate (airway/breathing/circulation, major haemorrhage protocol if massive)
  • Local haemostatic measures, tranexamic acid, reverse per agent
  • WARFARIN major bleeding: 4-factor PCC (25-50 units/kg by INR/weight) PLUS IV vitamin K 5-10 mg - PCC acts fast, vitamin K sustains reversal; recheck INR after PCC
  • WARFARIN high INR, no bleeding: withhold +/- oral vitamin K per INR (e.g. INR >8 give 1-5 mg oral vitamin K); avoid routine PCC
  • DABIGATRAN major bleeding: idarucizumab 5 g IV (two 2.5 g vials); consider dialysis (dialysable); PCC if idarucizumab unavailable
  • FACTOR Xa INHIBITOR (apixaban/rivaroxaban/edoxaban) major bleeding: andexanet alfa (dose by agent/dose/timing) OR 4-factor PCC 50 units/kg if andexanet unavailable
  • Vitamin K deficiency bleeding (malnutrition, malabsorption, antibiotics, biliary obstruction): IV vitamin K + PCC/FFP if actively bleeding
  • Do NOT use FFP as primary warfarin reversal if PCC available (slower, volume, less complete); activated charcoal if DOAC ingested <2-4h
  • Restart anticoagulation when haemostasis secure - weigh thrombotic risk (andexanet carries thrombotic risk; mechanical valves need prompt re-anticoagulation plan)

Drugs & doses

4-factor prothrombin complex concentrate 25-50 units/kg IV (dose by INR and weight; e.g. 25 units/kg if INR 2-4, up to 50 units/kg if INR >6), max per product cap [verify local dose]
Vitamin K (phytomenadione) 5-10 mg by slow IV injection for warfarin major bleeding; 1-5 mg oral for high INR without bleeding [verify local dose]
Idarucizumab 5 g IV (2 x 2.5 g) - specific dabigatran reversal
Andexanet alfa IV - low dose (400 mg bolus + 480 mg infusion) or high dose (800 mg bolus + 960 mg infusion) depending on agent/dose/timing of last Xa-inhibitor dose [verify local dose]
Tranexamic acid 1 g IV over 10 min (adjunct, esp. mucosal/trauma/GI bleeding) [verify local dose]
Fresh frozen plasma 15 mL/kg only if PCC unavailable [verify local dose]
Fibrinogen/cryoprecipitate if fibrinogen <1.5 g/L in major haemorrhage

Disposition

Major bleeding -> resus then admit (ICU/HDU, relevant specialty, e.g. neurosurgery for ICH). Involve haematology early. Plan timing of anticoagulation resumption.

Complications & pitfalls

  • Thromboembolism after reversal (PCC/andexanet)
  • Ongoing/rebound bleeding (short half-life reversal vs long DOAC effect)
  • Anaphylaxis to vitamin K if given rapid IV (give slowly)
  • Volume overload from FFP
  • Valve thrombosis if anticoagulation not resumed appropriately

Exam pearls

  • Warfarin major bleed = 4F-PCC + IV vitamin K together (PCC is fast but transient; vitamin K is slow but lasting) - ANZ/BSH guidance
  • Idarucizumab for dabigatran; andexanet alfa or PCC for apixaban/rivaroxaban/edoxaban
  • A normal thrombin time excludes significant dabigatran effect; normal anti-Xa excludes significant Xa-inhibitor effect
  • For intracranial haemorrhage on any anticoagulant, reverse first - do not wait for levels
  • Andexanet alfa is costly, prothrombotic and may interfere with heparin for subsequent surgery - involve haematology; PCC is the common pragmatic alternative
  • Vitamin K IV must be given slowly to avoid anaphylactoid reaction

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.